Teva Says Wyeth Patent Deal Doesn't Step On Antitrust Law

Law360, New York (April 9, 2012, 8:47 PM EDT) -- Teva Pharmaceuticals USA Inc. on Friday moved to toss direct purchasers' claims in multiple class actions and individual suits accusing it of conspiring with Wyeth LLC to delay a generic antidepressant's entry into the market, arguing that settling patent litigation with Wyeth didn’t violate antitrust law.

In a series of coordinated class actions and individual suits brought by direct purchasers, Teva maintains it did not enter into a sham settlement with Pfizer Inc. unit Wyeth in order to delay the entry of Effexor XR into the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.